Xilio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Xilio Therapeutics, Inc. (XLO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 59.52 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 50.24K shares, a 94.15% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 9.28K shares, a 99.67% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -1.32M shares, a 365.87% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 171.00K shares, a 34.42% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.57M shares, a 0.63% decline from fiscal 2024.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.58M shares, a 30.95% decline from fiscal 2023.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.74M shares, a 114.20% increase from fiscal 2022.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.75M shares, a 53.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 50.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 59.52K shares 10-Q · filed 2026-08-12 | -1.26M shares derived: sum of 3 quarters · filed 2026-08-12 | -1.09M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 9.28K shares 10-Q · filed 2026-05-12 | -1.31M shares derived: sum of 2 quarters · filed 2026-05-12 | -1.14M shares derived: sum of 3 quarters · filed 2026-05-12 | -278.19K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | -1.32M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -1.15M shares derived: sum of 2 quarters · filed 2026-03-23 | -287.47K shares derived: sum of 3 quarters · filed 2026-03-23 | 2.57M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 171.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 1.03M shares derived: sum of 2 quarters · filed 2025-11-13 | 3.88M shares 10-Q · filed 2025-11-13 | 4.38M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 859.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 3.71M shares 10-Q · filed 2025-08-14 | 4.21M shares derived: sum of 3 quarters · filed 2025-08-14 | 4.47M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 2.85M shares 10-Q · filed 2025-05-08 | 3.35M shares derived: sum of 2 quarters · filed 2025-05-08 | 3.61M shares derived: sum of 3 quarters · filed 2025-05-08 | 4.81M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 495.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 756.35K shares derived: sum of 2 quarters · filed 2025-03-11 | 1.95M shares derived: sum of 3 quarters · filed 2025-03-11 | 2.58M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 260.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.46M shares derived: sum of 2 quarters · filed 2024-11-07 | 2.09M shares 10-Q · filed 2024-11-07 | 2.09M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 1.20M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.83M shares 10-Q · filed 2024-08-08 | 1.83M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.89M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 626.97K shares 10-Q · filed 2024-05-14 | 626.97K shares derived: sum of 2 quarters · filed 2024-05-14 | 2.69M shares derived: sum of 3 quarters · filed 2024-05-14 | 2.84M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 2.06M shares derived: sum of 2 quarters · filed 2024-04-01 | 2.21M shares derived: sum of 3 quarters · filed 2024-04-01 | 3.74M shares 10-K · filed 2024-04-01 |
| 2023-09-30 | 2.06M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.21M shares derived: sum of 2 quarters · filed 2023-11-09 | 3.74M shares 10-Q · filed 2023-11-09 | 3.87M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 146.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 1.68M shares 10-Q · filed 2023-08-14 | 1.81M shares derived: sum of 3 quarters · filed 2023-08-14 | 2.06M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 1.53M shares 10-Q · filed 2023-05-09 | 1.66M shares derived: sum of 2 quarters · filed 2023-05-09 | 1.91M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.40M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 134.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 382.55K shares derived: sum of 2 quarters · filed 2023-03-02 | 870.54K shares derived: sum of 3 quarters · filed 2023-03-02 | 1.75M shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 248.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 736.09K shares derived: sum of 2 quarters · filed 2022-11-09 | 1.61M shares 10-Q · filed 2022-11-09 | 2.40M shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 487.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 1.36M shares 10-Q · filed 2022-08-09 | 2.16M shares derived: sum of 3 quarters · filed 2022-08-09 | |
| 2022-03-31 | 874.83K shares 10-Q · filed 2022-05-12 | 1.67M shares derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | 793.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 3.79M shares 10-K · filed 2022-03-01 | ||
| 2021-09-30 | 2.99M shares 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |